MedTrace Logo

Exploratory Study for Allergy Relief Onset

NCT02722083 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-12-12

No results posted yet for this study

Summary

The purpose of the study is to explore the onset of effect of an antihistamine in a controlled environment.

Conditions

  • Rhinitis, Allergic

Interventions

DRUG

Chlorpheniramine maleate (BAY X002134)

4 mg tablet, single dose, orally

DRUG

Placebo

placebo tablet, single dose, orally

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-07
Primary Completion
2016-05-27
Completion
2016-07-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02722083 on ClinicalTrials.gov